MergerAug 3, 2026, 06:36 AM
Supernus to Merge with Indivior; Q2 Revenue +32% to $219.1M
AI Summary
Supernus Pharmaceuticals announced a definitive agreement to combine with Indivior Pharmaceuticals, Inc. in an all-stock merger of equals, creating a diversified CNS biopharmaceutical company. Concurrently, Supernus reported strong second-quarter 2026 financial results, with total revenues increasing 32% to $219.1 million, driven by its four growth products. Despite the revenue growth, the company reported a net loss of $58.4 million due to a $54.9 million intangible asset impairment charge. Supernus also raised its full-year 2026 financial guidance.
Key Highlights
- Supernus to merge with Indivior Pharmaceuticals in an all-stock merger of equals.
- Total revenues increased 32% to $219.1 million in Q2 2026.
- Combined revenues of four growth products rose 52% to $175.7 million.
- Qelbree net sales increased 15% to $89.2 million in Q2 2026.
- ZURZUVAE collaboration revenue was $35.4 million in Q2 2026.
- ONAPGO net product sales were $13.5 million in Q2 2026.
- Net loss was $58.4 million ($1.01 diluted loss per share) in Q2 2026.
- Full-year 2026 total revenue guidance raised to $860M-$890M.
Price Impact
More from SUPN